Assessment of the In Vivo Efficacy of WCK 5222 (Cefepime-Zidebactam) against Carbapenem-Resistant Acinetobacter baumannii in the Neutropenic Murine Lung Infection Model

We evaluated the in vivo efficacy of human-simulated WCK 5222 (cefepime-zidebactam) against cefepime-resistant Acinetobacter baumannii strains (n = 13) in the neutropenic murine lung infection model. Twelve isolates were meropenem resistant. In control animals and those that received cefepime or zidebactam alone, the mean bacterial growth at 24 h was >2 log(10) CFU/lung compared with 0-h controls (6.32 +/- 0.33 log(10) CFU/lung). WCK 5222 produced a decline in the bacterial burden for all isolates (mean reduction, -3.34 +/- 0.85 log(10) CFU/lung) and demonstrated remarkable potency.